Leo Pharma and Astrazeneca keep future plans tight for tralokinumab
Neither Leo Pharma nor Astrazeneca wants to reveal the future plans for tralokinumab, which has just been approved as an atopic eczema treatment in the US. The drug has blockbuster potential in the approved indication, and while other indications might be considered, Astrazeneca retains the rights for several lucrative indications.
by ULRICH QUISTGAARD, translated by daniel pedersen
The US approval of Leo Pharma's eczema drug, tralokinumab, has been a popular topic at the Danish dermatology firm, which has clear blockbuster expectations for the treatment.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
